Skip to main
VRDN

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics is expected to benefit from the positive results of elegrobart in clinical trials and the company's strong financial position and expanding pipeline. However, competition in the market and a lowered target price may pose challenges for the company's success. Despite these challenges, Viridian Therapeutics has the potential for success in the future and its differentiated drug, elegrobart, may serve as a promising treatment option for patients with thyroid eye disease.

Bears say

Viridian Therapeutics is developing two anti-IGF-1R product candidates for the treatment of thyroid eye disease, but there are several potential concerns surrounding the company. First, the dosing regimen for veligrotug may be burdensome for patients, requiring 12 infusions over 22 weeks. Additionally, there is still incomplete data available for the company's other product candidate, elegrobart. Furthermore, Viridian faces sustainability issues, including data transparency and diversity of management, that may hinder its long-term success. These risks, along with potential competition and manufacturing challenges, make for a negative outlook on the company's stock.

Viridian Therapeutics (VRDN) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 11 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.